Cas:172822-29-6 Ent-Aprepitant manufacturer & supplier

Chemical Name:Ent-Aprepitant

CAS.NO:172822-29-6

Synonyms:Emend;Aprepitant-MK-0869;ent-Aprepitant;MK0869;Aprepitant Impurity 1

Molecular Formula:C₂₃H₂₁F₇N₄O₃

Molecular Weight:534.42700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:83.50000

Exact Mass:534.15000

LogP:5.30230

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Emend chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Aprepitant Impurity 1 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Aprepitant Impurity 1 Use and application,MK0869 technical grade,usp/ep/jp grade.

Related News: The company��s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Ent-Aprepitant manufacturer ��Inceptua Medicines Access is delighted to be selected as Onconova��s partner for the Pre-approval Access Program for rigosertib. Ent-Aprepitant supplier The company��s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Ent-Aprepitant vendor The CRL for the Cabenuva injection, containing two active ingredients cabotegravir and Janssen��s rilpivirine, follows U.S. market approval in April for its once-a-day pill Dovato, also a two-drug combination. Ent-Aprepitant factory The company��s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments.